Each year, hundreds of thousands of people undergo bladder cancer surgery and then wait — uncertain whether the operation truly succeeded or whether invisible remnants of disease are already preparing a return. Researchers in London have brought a new kind of clarity to that uncertainty: a blood test capable of detecting circulating tumor DNA, the genetic whisper of surviving cancer cells, can now identify which patients face genuine relapse risk and which may safely forgo further treatment. The study, published in Nature, found that patients with detectable ctDNA who received immunotherapy li
Blood test shows promise in predicting bladder cancer recurrence after surgery
Bladder cancer affects approximately 573,000 people globally with 212,000 deaths annually; high post-surgery relapse rates leave many patients with undetected residual disease.
A simple blood draw that tells you whether your surgery worked
Mark
So this blood test detects cancer DNA floating in the bloodstream. How does that actually work?
Mimi
Cancer cells shed genetic material as they die or divide. That DNA circulates in the blood in tiny amounts. The test can find it and measure it. If it's there after surgery, it means cancer cells survived the operation.
Luke
But how sensitive is it? Can it detect one cancer cell's worth of DNA, or does it need a certain threshold before it shows up positive?
Mimi
The source doesn't specify the sensitivity threshold. We know it worked in this study population, but the exact detection limits aren't detailed.
Mark
And the survival numbers—25.8 months versus 15.8 months for ctDNA-positive patients on immunotherapy. That's a real difference.
Mimi
It is. But that's still measured in months, not years. The immunotherapy helped, but it's not a cure.
Luke
Right. And we should note: this was a subgroup analysis of 581 patients from larger trials. The drug didn't help the overall study population. It only helped the ctDNA-positive subset.
Mark
So the blood test is what makes the difference—it identifies who benefits from the drug.
Mimi
Exactly. Without it, you'd be giving immunotherapy to everyone, including people who don't need it and won't benefit from it.
Luke
Has this been validated in other cancer types yet?
Mimi
Not yet. The source says further studies are needed. This is bladder cancer specifically, and the findings would need to be tested elsewhere before becoming standard practice.
Mark
So what's the timeline? When might patients actually have access to this?
Luke
That's unknown. The source doesn't say. Validation studies take years. This is promising, but it's not in clinics yet.
Il Polso
- Bladder cancer kills 212,000 people annually, and surgery's apparent success often masks microscopic disease that imaging cannot see — leaving patients and doctors in a prolonged, dangerous uncertainty.
- A blood test measuring circulating tumor DNA proved more accurate than traditional radiology at detecting residual cancer after surgery, exposing a critical gap in how post-operative care has long been managed.
- Among the 581 patients studied, those who tested positive for ctDNA and received the immunotherapy atezolizumab saw overall survival climb from 15.8 to 25.8 months — a difference measured in lives, not statistics.
- For ctDNA-negative patients, immunotherapy offered no benefit whatsoever, revealing that the test can protect the cured from unnecessary toxicity just as powerfully as it can direct treatment toward those who need it.
- The research is not yet complete — funded by Roche and Genentech, it requires broader validation before reshaping clinical practice, but the trajectory points toward a more precise and humane standard of post-surgical cancer care.
Each year, hundreds of thousands of people undergo bladder cancer surgery and then wait — uncertain whether the operation truly succeeded or whether invisible remnants of disease are already preparing a return. Researchers in London have brought a new kind of clarity to that uncertainty: a blood test capable of detecting circulating tumor DNA, the genetic whisper of surviving cancer cells, can now identify which patients face genuine relapse risk and which may safely forgo further treatment. The study, published in Nature, found that patients with detectable ctDNA who received immunotherapy lived significantly longer than those left under observation alone — while those without it gained nothing from the drug, and needed nothing from it. It is a step toward a medicine that listens more carefully before it acts.
When a surgeon removes a bladder tumor, the patient goes home — but invisible cancer cells often remain, too small for imaging to find, drifting through the bloodstream until they establish new tumors elsewhere. For decades, doctors have had no reliable way to distinguish the truly cured from those harboring this silent residual disease. A new blood test may finally change that.
Researchers at Queen Mary University of London and Barts Health NHS Trust, led by Professor Tom Powles, showed that measuring circulating tumor DNA — genetic material shed by surviving cancer cells into the blood — can identify which bladder cancer patients face the highest risk of relapse after surgery. The findings, published in Nature, examined 581 patients across two clinical trials testing whether the immunotherapy drug atezolizumab could prevent recurrence. The logic is direct: if cancer remains, it leaves traces in the blood. Find those traces, and you've found the patients in danger.
The results were striking. Patients who tested positive for ctDNA and received atezolizumab saw overall survival extend from 15.8 to 25.8 months. Those who tested negative gained nothing from the drug — and needed nothing from it. The blood test also outperformed traditional imaging at detecting disease relapse, exposing a long-standing blind spot in post-surgical oncology.
The implications reach beyond bladder cancer. Rather than treating all high-risk patients prophylactically — or waiting passively for a tumor to reappear on a scan — doctors could act on actual molecular evidence. Those with detectable ctDNA receive intervention. Those without it are spared unnecessary toxicity. The approach is more precise, less wasteful, and more attuned to the individual patient's reality. Further validation across larger populations is still needed before this becomes standard practice, but the promise is tangible: a simple blood draw that tells you whether surgery worked, and whether more help is required.
Surgeons remove a bladder tumor, and the patient goes home. But invisible cancer cells often remain—fragments so small they escape detection by standard imaging, drifting through the bloodstream and eventually establishing new tumors elsewhere. For decades, doctors have had no reliable way to know which patients are truly cured and which are harboring this molecular residual disease, the microscopic aftermath of surgery. A new blood test may change that calculus entirely.
Researchers at Queen Mary University of London and Barts Health NHS Trust, led by Professor Tom Powles, have shown that detecting circulating tumor DNA—genetic material shed by cancer cells into the blood—can identify which bladder cancer patients face the highest risk of relapse after surgery. The findings, published in Nature, suggest a path toward precision treatment: giving immunotherapy only to those who need it, sparing others from unnecessary toxicity. Globally, bladder cancer kills roughly 212,000 people annually out of 573,000 diagnosed cases. Surgery is often the first line of treatment for muscle-invasive disease, the most dangerous form, yet relapse rates remain stubbornly high because complete tumor removal is difficult to achieve.
The study examined 581 patients enrolled in two clinical trials testing whether the immunotherapy drug atezolizumab could prevent recurrence in high-risk cases. Researchers used a blood test to measure circulating tumor DNA, or ctDNA, shortly after surgery. The logic is straightforward: if cancer cells remain in the body, they shed genetic fragments into the bloodstream. Detect those fragments, and you've found the patients in trouble. The team discovered that patients whose blood tested positive for ctDNA faced substantially higher recurrence risk than those who tested negative—a finding that proved more accurate than traditional imaging at spotting disease relapse.
What happened next is where the story gains real weight. When doctors gave atezolizumab to ctDNA-positive patients, the results were striking. Disease-free survival stretched from 4.4 months to 5.9 months. Overall survival jumped from 15.8 months to 25.8 months. For ctDNA-negative patients, the drug made no meaningful difference—they did just as well with observation alone. This distinction matters enormously. It means the blood test can separate patients who genuinely need aggressive follow-up treatment from those whose surgery has already done its job.
The current clinical reality is blunt: doctors cannot easily tell who is cured and who is not. Many patients who are actually cancer-free end up receiving additional treatments anyway, enduring side effects from drugs they didn't need. Meanwhile, other patients with residual disease go undetected until imaging finally shows a new tumor—by which point the cancer has had months or years to spread. Powles noted that ctDNA measurement proved more accurate than radiology at identifying disease relapse, a finding that could reshape how oncologists approach post-surgical care.
The implications extend beyond bladder cancer. If validated across other tumor types, this approach could fundamentally alter cancer treatment philosophy. Instead of treating all high-risk patients prophylactically or waiting passively for relapse, doctors could offer personalized intervention based on actual evidence of residual disease. Patients with detectable ctDNA would receive immunotherapy. Patients without it would avoid unnecessary toxicity. The system becomes more precise, less wasteful, more humane.
But the research is not yet finished. The study was funded by Roche and Genentech, and further validation will be required before this blood test becomes standard practice. Researchers must confirm the findings in larger populations and determine whether ctDNA detection can guide treatment decisions across different cancer types. The promise is real—a simple blood draw that tells you whether your surgery worked, and whether you need more help. The next phase is proving it holds up.
Citazioni salienti
These novel findings demonstrate ctDNA as a marker for residual disease and response to atezolizumab. These findings may change our understanding of post-surgical cancer care.— Professor Tom Powles, study lead researcher
Vuoi la storia completa?
Leggi l'originale su News-Medical.net ↗
Health & Medicine